The new oral antidiabetics such as sodium—glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP1-RA) seem to be safe according to the first studies and are promising, especially in the setting of transplant vasculopa-thy (GLP1-RA) or renal failure (SGLT2 inhibitors) after HTx [101, 102]. Here, GLP1R is linked to Renal insufficiency.